Fig. 5.

Lung CD24⁺ cDC2s inhibit cDC1-mediated eosinophil migration via TGF-β1. a, b Quantification of eosinophils in Balf and lung from TGF-β1^fl/flCD11c^Cre (empty circle) and TGF-β1^fl/fl (solid circle) mice 2.5 days (a, n = 5–6 mice per group) or 1.5 days (b, n = 4–5 mice for saline groups and n = 7 mice for OVA groups) after the first OVA challenge. c mRNA expression of TGF-β1 by pulmonary cDC1, CD24⁺ cDC2, CD24⁻CD11b⁺ DC2, MC, IM and AM populations separated from C57BL/6 mice 2.5 days after the first OVA (solid rectangle) or saline (empty rectangle) challenge. d mRNA expression of TGF-β1 by pulmonary CD24⁺ cDC2s separated from C57BL/6 mice 0, 1.5, or 2.5 days after the first OVA challenge. mRNA expression is relative to the expression of cDC1s (c) or CD24⁻CD11b⁺ DC2s (d) from saline-treated mice. n = 3–5 per group. e Counts of CD24⁺ cDC2s in lungs from C57BL/6 mice 0, 1.5, or 2.5 days after the first OVA challenge. f Counts of eosinophils recruited into the air pouches injected with pulmonary cDC1s or CD24⁺ cDC2s (1 × 10⁴ cells, 200 μl) purified from C57BL/6 mice 2.5 days after the first OVA challenge with anti-TGF-β1 (10 μg per ml) antibody or mouse IgG1 isotype control. n = 4–6 mice per group. g Counts of eosinophils recruited into the air pouches injected with pulmonary cDC1s, and CD24⁺ cDC2s (1 × 10⁴ cells, 200 μl) purified from TGF-β1^fl/flCD11c^Cre (KO) and TGF-β1^fl/fl (WT) mice 2.5 days after the first OVA challenge. n = 4–6 mice per group. h mRNA expression of CCL17 and CCL22 chemokines by lung cDC1s (SiglecF⁻CD11c⁺IA/IE⁺CD103⁺CD11b⁻), separated from TGF-β1^fl/flCD11c^Cre (solid rectangle) and TGF-β1^fl/fl (empty rectangle) mice 2.5 days after the first OVA challenge. n = 4–5 per group. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired Student’s t test. Means ± SD are shown. Data represent two (c, d) and three (a, b, e–h) independent experiments